Inhibikase Therapeutics, Inc.
IKTDrugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 13, 2026
9dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
IKT Earnings Report
EPS Est: $-0.09 | FQ end 2026-06
How IKT's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
IKT-001 | Phase 3 | Pulmonary Arterial Hypertension | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Inhibikase Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Inhibikase Therapeutics, Inc.'s (IKT) pipeline across Phase 3. Its lead program is IKT-001 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Inhibikase Therapeutics, Inc.'s next FDA catalyst?→
Inhibikase Therapeutics, Inc.'s (IKT) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IKT biotech catalysts?→
Add IKT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Inhibikase Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.